Gregory R. Chiklis
6 Papers
20 Citations
Gregory R. Chiklis is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
Maggie Li,Evan J. Beck,Oliver Laeyendecker,Yolanda Eby,Aaron A.R. Tobian,Patrizio Caturegli,C. J. Wouters,Gregory R. Chiklis,William Block,Robert O McKie,Michael J. Joyner,Tim Wiltshire,Allan B. Dietz,Thomas J. Gniadek,Arell Shapiro,Anusha Yarava,Karen Lane,Daniel F. Hanley,Evan M. Bloch,Shmuel Shoham,Edward R. Cachay,Barry Meisenberg,Moises A. Huaman,Yuriko Fukuta,Bela Patel,Sonya L. Heath,Adam C. Levine,James H. Paxton,Shweta Anjan,Jonathan M. Gerber,Kelly A. Gebo,Arturo Casadevall,Andrew Pekosz,David Sullivan +33 more
TL;DR: High-titer CCP neutralizes SARS-CoV-2 variants despite no previous donor exposure to the variants, and antibody levels in the upper 10% as well as 100% of the post-delta COVID-19/post-vaccination units and the hyperimmunoglobulin effectively neutralized all three variants.
Laser induced breakdown spectroscopy for the rapid detection of SARS-CoV-2 immune response in plasma
Kim Berlo,Wen-xiu Xia,F. Zwillich,Erin Gibbons,R. Gaudiuso,Ebo Ewusi-Annan,Gregory R. Chiklis,Noureddine Melikechi +7 more
TL;DR: In this paper , a combination of laser induced breakdown spectroscopy (LIBS) with machine learning can distinguish plasma of donors who previously tested positive for SARS-CoV-2 by RT-PCR from those who did not, with up to 95% accuracy.
Patent
Nucleic acid amplification controls
Gregory R. Chiklis,James C. D. Hengst +1 more
- 17 Oct 2001
TL;DR: In this article, a positive control material for nucleic acid amplification based detection of microorganisms in biological samples is presented, which comprises purified microorganisms that are rendered non-infectious but are amenable to NCA.
16
High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern
Maggie Li,Evan J. Beck,Oliver Laeyendecker,Yolanda Eby,Aaron A.R. Tobian,Patrizio Caturegli,C. J. Wouters,Gregory R. Chiklis,William Block,R. McKie,Michael J. Joyner,Tim Wiltshire,Allan B. Dietz,Thomas J. Gniadek,Arell Shapiro,Anusha Yarava,Karen Lane,Daniel F. Hanley,Evan M. Bloch,Shmuel Shoham,Edward R. Cachay,Barry Meisenberg,Moises A. Huaman,Yuriko Fukuta,Bela Patel,Sonya L. Heath,Adam C. Levine,James H. Paxton,Shweta Anjan,Jonathan M. Gerber,Kelly A. Gebo,Arturo Casadevall,Andrew Pekosz,David Sullivan +33 more
TL;DR: High-titer CCP neutralizes SARS-CoV-2 variants despite no previous donor exposure to the variants, and antibody levels in the upper 10% as well as 100% of the post-delta COVID-19/post-vaccination units and the hyperimmunoglobulin effectively neutralized all three variants.
Patent
Microorganisms rendered non-pathogenic
Gregory R. Chiklis,James C. D. Hengst +1 more
- 17 Oct 2001
TL;DR: In this article, a positive control material for nucleic acid amplification based detection of microorganisms in biological samples is presented, which comprises purified microorganisms that are rendered non-infectious but are amenable to NCA.